logo-loader
viewGenedrive PLC

Firms across the coronavirus treatment chain see share prices surge

Companies involved in diagnostics, drug development and medical equipment provision have all seen strong stock price rises as the world grapples with the pandemic

Genedrive PLC - Firms across the coronavirus treatment chain see share prices surge

With the race on to find treatments and possible cures for the coronavirus pandemic, a number of small and mid cap firms have taken up positions in the development chain aiming to fight the virus and alleviate difficulties for both patients and doctors.

Areas in the treatment cycle include diagnostics, drug development, inoculation technology and equipment to help medics treat the illness.

Diagnostics

One firm from its efforts in battling coronavirus is Genedrive PLC (LON:GDR), which last week said a clinically validated high throughput format for its coronavirus test could be available in “approximately eight weeks”.

The firm’s 96 SARS-COV-2 test, which can determine whether someone is infected with coronavirus, is freeze dried, which the company said provides it with a “significant logistical advantage for rapid shipment and global distribution”.

Investors have been more than optimistic about the prospects of the test, with Genedrive shares having risen around 233% to 30p since the beginning of March.

Meanwhile, fellow AIM-listed biotech Novacyt SA (LON:NCYT) has surged 47.5% to 206.5p in the same period as it develops its own coronavirus test.

The company’s efforts took another step forward last week when it secured a manufacturing agreement for the test with molecular diagnostics group Yourgene Health PLC (LON:YGEN).

Drug developers and inoculators

Moving from diagnostics to treatment, multiple junior biotechs are moving forward with their own potential therapies that could alleviate the symptoms of coronavirus.

Synairgen PLC (LON:SNG) has recently raised £14mln to fund the trial of its interferon-beta treatment in coronavirus patients.

The drug, SNG001, is an inhaled formulation of interferon-beta-1a and is currently being developed to treat people with chronic obstructive pulmonary disease (COPD) that also have respiratory viral infections such as coronavirus.

Hopes that the treatment will protect COPD sufferers from lung damage resulting from a coronavirus infection have driven the stock 214% higher to 55p over the last month.

Similarly, Faron Pharmaceuticals Oy (LON:FARN) has surged 37% to 470p on the back of its own interferon-beta treatment, Traumakine, which is intravenously administered and targets acute respiratory distress syndrome or ARDS, something that has become common among severely ill patients in the current coronavirus outbreak.

An earlier phase III trial missed its endpoints, however, since then Faron has received approval from the US regulator to resubmit Traumakine for a new trial without glucocorticoids.

The company believes this will demonstrate a benefit in people affected by coronavirus and other viral infections.

Meanwhile, N4 Pharma PLC (LON:N4P) shares have gained a new lease of life, rising 83% to 5,8% since that start of March as the group kicks off a proof of concept study which will use a coronavirus DNA plasmid to demonstrate the ability of the firm’s Nuvec delivery system to act as a method of delivering a possible vaccine for the illness.

Medical equipment

Away from the treatment spheres, other firms are also benefiting from their technology being used to treat patients currently suffering from the illness until a vaccine can be developed.

LiDCO Group PLC (LON:LID) has jumped 86% to 9.8p over the last four weeks as the outbreak led to a surge in demand for its heart monitoring technology in China.

In early March, the company said its distribution partner in China, Beijing Gloryway Medical, had=s sold a small number of its monitors in Wuhan, where the virus originated, as a direct result of the epidemic.

Investment firms are also seeing increases in their share prices as their portfolio firms are approached to provide their services during the pandemic.

Intellectual property investor Tekcapital PLC (LON:TEK) has seen its shares rise 31% to 5.9p over the month, partly as a result of its portfolio company Belluscura, which earlier in March filed a patent for a portable oxygen enrichment system to treat patients suffering from respiratory illnesses brought on by infections such as coronavirus.

The firm also said last week that Belluscura could benefit from new guidance issued by the US Food and Drug Administration (FDA) which is aiming to expand the availability of ventilators as well as other respiratory devices during the pandemic.

Quick facts: Genedrive PLC

Price: 111.9199 GBX

AIM:GDR
Market: AIM
Market Cap: £58.18 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genedrive receives NHS grant to develop and implement point-of-care test

David Budd, chief executive of Genedrive PLC (LON:GDR) and Bill Newman, Professor of Translational Genomic Medicine at the University of Manchester discuss with Proactive Investors the grant awarded to Genedrive for a point-of-care pharmacogenetic test to avoid antibiotic-related hearing loss...

on 26/6/18

4 min read